

2cureX announces issuance of final patent completing the protection of the ChemoCellomics® technology.

Copenhagen, Denmark, 8 June 2010: 2cureX is pleased to announce that a second patent providing a complete protection of 2cureX's core ChemoCellomics® has been issued (EP1761783). To obtain as broad a coverage of the invention as possible two patent application were originally filed on the same day. It is a pleasure to see that both applications now have issued in full which provides a strong basis for 2cureX to finalize its first product, 2CX400 said Ole Thastrup, CEO of 2cureX.

The patents cover integration of chemistry and cells on any solid support. The chemistry can for example be large chemical libraries synthesized directly on the support or it can be collections of approved drugs. These libraries can then be interrogated for their influence on the associated cells. These cells can be of mammalian origin (e.g. patient cells) or they can be parasites or microorganisms. 2cureX is focusing its own development efforts toward bringing a cancer treatment selection technology to the market; but will at the same time investigate licensing opportunities outside the company's business scope.

"2cureX is pushing hard to move its first product towards clinical testing in colorectal cancer patients. When committing resources and establishing partnerships to fulfil such endeavor it is important for us to know that the technology is effectively protected" said Timm Jessen, CBO of 2cureX.

Contacts:

Ole Thastrup
Chief Executive Officer

Tel: +45 45822036
e-mail: ot@2curex.com

Timm Jessen
Chief Business Officer

Tel: +49 (4315) 606 448
e-mail: tj@2curex.com

About 2cureX

- 2cureX is a Danish life science company that was spun-out of Carlsberg in 2006
- 2cureX develops a technology for individualised treatment of patients with solid cancers
- 2cureX is engaged in a comprehensive network of technical and clinical partners to exploit the ChemoCellomics® technology